Fundraising setback for Stemline as it puts off IPO
This article was originally published in Scrip
Executive Summary
New York-based Stemline Therapeutics has decided now is not the right time to go to market, postponing its initial public offering in which it planned to raise up to $42 million by selling 3.5 million shares at $11 to $13 per share (scripintelligence.com, 23 July 2012).